Reports
Pivotal clinical trials for trastuzumab biosimilars
Biosimilars of Roche’s Herceptin (trastuzumab), a humanized monoclonal antibody are currently under development.
Pivotal clinical trials for rituximab biosimilars
Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.
German physicians not pressured to switch to biosimilar infliximab
Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research and advisory firm Decision Resources.
Pivotal clinical trials for bevacizumab biosimilars
Biosimilars of Roche’s Avastin (bevacizumab), a humanized monoclonal antibody, are currently under development.
Generics use in Italy could save Euros 1.4 billion per year
A report published by Italian generics association Assogenericion on 5 May 2015 points to the fact that generics are crucial in the containment of pharmaceutical expenditure in Italy.
Clinical programmes for oncology biosimilars
Biosimilars for oncology drugs are currently under development. These include biosimilars of blockbusters such as Roche’s Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab).
Doctors’ survey reveals lack of confidence in biosimilars
Online physician’s platform and community QuantiaMD survey of 300 primary care physicians and specialists in the US has found a lack of confidence concerning biosimilars.
Clinical programmes for anti-TNF biosimilars
Biosimilars for anti-tumour necrosis factor (anti-TNF) drugs are currently under development. These include biosimilars of blockbusters such as AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Remicade (infliximab).
Cost reductions due to biosimilars in Europe
Biosimilars have been approved in the European Union since 2006 in the classes of erythropoietin (EPO), human growth hormone (HGH), granulocyte colony-stimulating factor (G-CSF) and anti-tumour necrosis factor (anti-TNF). Despite the fact that they have been in use since 2006, the prices for EPO, HGH and G-CSF classes of drugs in some countries have not reduced by as much as some might have expected. There is also a significant variation between different countries in Europe [1].
Biosimilars penetration in Europe varies widely
The penetration of biosimilars in Europe varies widely between countries and therapy areas [1].
